Table 4 Relation between YKL-40 serum levels and others variables (demographic, clinical, laboratory and lung parameters, disease status, and comorbidities) of the patients with antisynthetase syndrome
Group 1 | Group 2 | P value | |||
|---|---|---|---|---|---|
n | Mean ± SD | n | Mean ± SD | ||
Demographic data | |||||
Gender (female) | 53 | 628.5 ± 363.6 | 11 | 691.3 ± 461.0 | 0.658 |
Ethnicity (Caucasian) | 47 | 572.5 ± 316.7 | 17 | 793.2 ± 468.2 | 0.111 |
Clinical parameters | |||||
Fever | 18 | 579.4 ± 343.8 | 46 | 664.3 ± 394.0 | 0.484 |
Raynaud phenomenon | 14 | 536.6 ± 361.8 | 50 | 677.4 ± 382.7 | 0.255 |
“Mechanic’s hands” | 7 | 658.6 ± 334.6 | 57 | 637 ± 389.2 | 0.891 |
Muscle involvement | 3 | 980.2 ± 178.7 | 61 | 625.6 ± 379.2 | 0.198 |
Joint involvement | 5 | 973.5 ± 602.1 | 59 | 610.4 ± 347.5 | 0.066 |
Laboratory parameters | |||||
Antinuclear factor | 12 | 685.7 ± 303.5 | 52 | 628.4 ± 398.4 | 0.674 |
Anti-Ro-52 | 35 | 663.9 ± 406.5 | 28 | 638.5 ± 348.0 | 0.818 |
Anti-Jo-1 | 11 | 728.4 ± 455.9 | 53 | 617.4 ± 359.7 | 0.414 |
Anti-PL-7 | 60 | 619.1 ± 377.6 | 4 | 876.1 ± 351.5 | 0.197 |
Anti-PL-12 | 60 | 627.2 ± 360.9 | 4 | 784.8 ± 595.5 | 0.431 |
Anti-EJ | 61 | 653.7 ± 380.8 | 3 | 320.4 ± 52.2 | 0.227 |
Lung involvement | |||||
Ground-glass | 18 | 658.2 ± 348.1 | 46 | 634.2 ± 392.6 | 0.851 |
Incipient pneumopathy | 24 | 695.9 ± 387.1 | 40 | 607.6 ± 376.4 | 0.437 |
Pulmonary fibrosis | 50 | 586.2 ± 335.7 | 14 | 826.2 ± 471.8 | 0.063 |
Treatment | |||||
Prednisone (current use) | 17 | 483.3 ± 222.6 | 46 | 684.2 ± 406.3 | 0.047 |
Immunosuppressives/biologicals | |||||
Azathioprine | 43 | 618.9 ± 354.7 | 21 | 676.5 ± 425.2 | 0.613 |
Mycophenolate mofetil | 54 | 648.4 ± 383.8 | 10 | 603.1 ± 375.2 | 0.750 |
Methotrexate | 52 | 606.3 ± 338.1 | 12 | 790.3 ± 521.9 | 0.337 |
Antimalarial | 61 | 645.3 ± 385.8 | 3 | 516.7 ± 91.7 | 0.643 |
Leflunomide | 62 | 642.1 ± 382.5 | 2 | 544.0 ± 0 | 0.801 |
Cyclosporine | 62 | 650.8 ± 381.1 | 2 | 388.7 ± 272.8 | 0.343 |
Cyclophosphamide | 63 | 644.0 ± 381.8 | 1 | 451.9 ± 0 | 0.621 |
Rituximab | 48 | 690.0 ± 364.8 | 16 | 537.0 ± 397.9 | 0.188 |
Comorbidities | |||||
Systemic arterial hypertension | 42 | 590.4 ± 379.9 | 22 | 742.5 ± 366.9 | 0.190 |
Diabetes mellitus | 52 | 645.1 ± 395.0 | 12 | 610.0 ± 283.2 | 0.823 |
Hypothyroidism | 61 | 628.0 ± 381.0 | 3 | 922.5 ± 205.8 | 0.286 |
Acute myocardial infarction | 61 | 641.6 ± 382.6 | 3 | 567.2 ± 0 | 0.848 |
Stroke | 63 | 645.2 ± 381.0 | 1 | 391.6 ± 0 | 0.513 |